Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best Choices

Kátia Roque
ORCID logo ,
Rossana Ruiz
ORCID logo ,
Luis Mas
,
Daniel Humberto Pozza
ORCID logo ,
Marina Vancini
,
José Antônio Silva
ORCID logo ,
Ramon Andrade De Mello
*
Version 1 : Received: 15 July 2023 / Approved: 18 July 2023 / Online: 19 July 2023 (02:48:47 CEST)

A peer-reviewed article of this Preprint also exists.

Roque, K.; Ruiz, R.; Mas, L.; Pozza, D.H.; Vancini, M.; Silva Júnior, J.A.; de Mello, R.A. Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices. Cancers 2023, 15, 4547. Roque, K.; Ruiz, R.; Mas, L.; Pozza, D.H.; Vancini, M.; Silva Júnior, J.A.; de Mello, R.A. Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices. Cancers 2023, 15, 4547.

Abstract

The advent of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), improving the prognosis of this disease and becoming a key part of the treatment, especially in the population without an oncogenic driver mutation. Two different groups of immune checkpoint inhibitors (ICIs) are used in lung cancer: Anti- Cytotoxic T-lymphocyte antigen-4 (Anti-CTLA 4) and Anti- T-cell receptor programmed cell death-1 or its ligand (Anti-PD-1 and Anti PD-L1). Here in, we review an uptodate on the use of immunotherapy for advanced NSCLC.

Keywords

Immune checkpoint inhibitors (ICIs); Non–small cell lung cancer (NSCLC); PD-1 , PD-L1; CTLA-4

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.